BIOLASE (NASDAQ:BIOL) Issues Earnings Results, Beats Expectations By $0.13 EPS

BIOLASE (NASDAQ:BIOL) released its earnings results on Wednesday. The medical technology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.13, Fidelity Earnings reports. BIOLASE had a negative return on equity of 159.26% and a negative net margin of 47.46%. The business had revenue of $8.65 million for the quarter.

NASDAQ BIOL traded down $0.02 during trading on Thursday, reaching $0.56. 190,700 shares of the company traded hands, compared to its average volume of 60,907. The company has a debt-to-equity ratio of 3.51, a quick ratio of 1.11 and a current ratio of 2.04. The stock’s 50 day moving average price is $0.79 and its two-hundred day moving average price is $1.39. The company has a market cap of $13.06 million, a price-to-earnings ratio of -0.66 and a beta of 2.19. BIOLASE has a 1-year low of $0.55 and a 1-year high of $2.87.

In related news, major shareholder Larry N. Feinberg acquired 17,391 shares of the firm’s stock in a transaction on Tuesday, October 29th. The shares were bought at an average cost of $57.50 per share, with a total value of $999,982.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 4.50% of the stock is currently owned by insiders.

A number of equities research analysts recently weighed in on BIOL shares. Ascendiant Capital Markets set a $3.00 target price on BIOLASE and gave the stock a “buy” rating in a research report on Monday, August 12th. ValuEngine raised BIOLASE from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. Finally, Zacks Investment Research downgraded BIOLASE from a “buy” rating to a “hold” rating in a research report on Wednesday, October 9th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $2.17.


BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.

Recommended Story: The benefits and drawbacks of dollar cost averaging

Earnings History for BIOLASE (NASDAQ:BIOL)

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with's FREE daily email newsletter.